比较瑞舒伐他汀和阿托伐他汀对冠心病(CHD)伴高脂血症的降脂效果

Comparison of the Effects of Rosuvastatin and Atorvastatin on Coronary Heart Disease(CHD) with Hyperlipidemia

目的对比舒伐他汀和阿托伐他汀对冠心病(CHD)伴高脂血症的降脂效果。方法方便选取该院2014年2月—2016年12月诊治的80例CHD伴高血脂患者为研究对象,将患者随机分为观察组与对照组,每组患者40例,对照组患者采用阿托伐他汀治疗,剂量20 mg/d,观察组患者则采用瑞舒伐他汀治疗,剂量10 mg/d,比较两组患者的降脂效果。结果治疗后,观察组患者TG(1.88±0.46)mmol/L,对照组患者TG(2.12±0.39)mmol/L差异有统计学意义(P<0.05);观察组患者的TC(1.35±0.22)mmol/L、LDL-C(2.62±0.33)mmol/L,对照组患者TC(1.08±0.21)mmol/L、LDL-C(3.02±0.45)mmol/L,差异有统计学意义(P<0.05);观察组不良反应发生率为7.5%,对照组不良反应发生率为10.0%,数据差异无统计意义(P>0.05)。结论瑞舒伐他汀是一种降脂效果较强的药物,安全性高,值得推广。

Objective This paper tries to compare the rosuvastatin and atorvastatin on coronary heart disease（CHD） lipidlowering effect with hyperlipidemia. Methods 80 patients with CHD and hyperlipidemia in this hospital from February 2014 to December 2016 were convenient selected and were randomly divided into the observation group and the control group,with 40 cases in each group, patients in the control group using atorvastatin treatment with dose of 20 mg/d, patients in the observation group were treated with rosuvastatin with the dose of 10 mg/d, and the lipid-lowering effects of the two groups were compared. Results After the treatment, the TG of patients in the observation group was（1.88±0.46）mmol/L, the control group was（2.12±0.39）mmol/L, the difference was statistically significant（P〈0.05）; TC in the observation group was（1.35±0.22）mmol/L, LDL-C was（2.62±0.33）mmol/L, the control group of（1.08±0.21）mmol/L, LDL-C（3.02±0.45）mmol/L, with statistical difference（P〈0.05）; the incidence of adverse reactions was 7.5%, the control group was 10.0%, the difference was not statistically significant（P〈0.05）. Conclusion Rosuvastatin has strong lipid-lowering effect, with high safety, therefore it is worthy of promotion.